Polycystic ovary syndrome — evidence across compounds
Every compound the Institute assesses in polycystic ovary syndrome, with its certainty rating.
§2Evidence across compounds
Every compound the Institute assesses in this indication, with the effect as recorded, the certainty rating and the contributing trials. Effects are reported on the anchor outcome where the contributing trials measured it and on the outcome the trial actually reported where they did not.
Table 1. Compounds assessed in polycystic ovary syndrome, ordered by certainty.
| Compound | Effect as recorded | Interval as reported | Certainty | Trials |
|---|---|---|---|---|
| GonadorelinEndogenous decapeptide, gonadotropin-releasing hormone | Pulsatile administration by pump induces ovulation in hypothalamic amenorrhoea with reported ovulation rates above 80 % per cycle in selected patients | observational and small controlled series | Moderate | 1 |
| Kisspeptin-10Endogenous decapeptide, KISS1 receptor agonist | Kisspeptin-54 has been used as an oocyte-maturation trigger in assisted reproduction with reported reduction in ovarian hyperstimulation risk compared with human chorionic gonadotropin | small controlled studies; the decapeptide and the 54-residue peptide are not interchangeable | Low | 2 |
| Estimates in this table are not on a common scale and must not be subtracted from one another. Where a comparison between two compounds has been made directly, it appears in a synthesis and not here. | ||||
§2.1Syntheses bearing on this indication
No evidence synthesis addresses this indication.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- D’Hondt M, Bracke N, Taevernier L, Gevaert B, Verbeke F, Wynendaele E, De Spiegeleer B. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis 2014;101:2–30. doi:10.1016/j.jpba.2014.06.012 · PMID 25044089
- Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharmaceutical Research 2010;27(4):544–575. doi:10.1007/s11095-009-0045-6 · PMID 20143256
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.